<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503033</url>
  </required_header>
  <id_info>
    <org_study_id>2015-523-00AU1</org_study_id>
    <nct_id>NCT02503033</nct_id>
  </id_info>
  <brief_title>A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies</brief_title>
  <official_title>A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of HMPL-523 administered&#xD;
      to patients with relapsed or refractory Hematologic Malignancies&#xD;
&#xD;
      To determine the maximum tolerated dosage/recommended phase 2 dosage and characterize the&#xD;
      dose limited toxicities associated with HMPL-523 when administered to patients with relapsed&#xD;
      or refractory Hematologic Malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion&#xD;
      stage (stage 2).&#xD;
&#xD;
      Dose-escalation stage (stage 1). The conventional 3+3 design (3 patients per dose cohort,&#xD;
      with the potential to add additional 3 patients to the same cohort to further evaluate&#xD;
      toxicity) will be applied for dose escalation and maximum tolerated dosage determination.&#xD;
      Approximately 18 to 27 evaluable patients will be enrolled. The actual number of patients&#xD;
      depends on the dose limited toxicities situation as well as the maximum tolerated dosage&#xD;
      reached at this stage.&#xD;
&#xD;
      Dosing will include QD (quaque die) and bis in die (BID) cohorts. A cycle of study treatment&#xD;
      will be defined as 28 days of continuous dosing.&#xD;
&#xD;
      Dose-expansion stage (stage 2). In this stage, approximately 40 patients with B-cell&#xD;
      Non-Hodgkin's Lymphomas or Chronic Lymphocytic Leukemia will be enrolled with 600mg once&#xD;
      daily as starting dose. The tumor types of the expansion stage are restricted to Chronic&#xD;
      lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL), Mantle cell lymphoma (MCL),&#xD;
      Follicular Lymphoma (FL) (Grade 1-3a), Marginal zone lymphoma (MZL) and Waldenstrom's&#xD;
      macroglobulinemia / Lymphoplasmacytic lymphoma (WM/LPL). Subjects will receive HMPL-523 600mg&#xD;
      once daily with every 28-day treatment cycle until disease progression, death, or intolerable&#xD;
      toxicity, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dose limited toxicities evaluated with NCI CTCAE v4.03</measure>
    <time_frame>within 28days after the first dose</time_frame>
    <description>Incidence of dose limited toxicities and associated dose of HMPL-523</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>maximum plasma concentration calculated with Blood samples</measure>
    <time_frame>within 29 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach maximum concentration calculated with Blood samples</measure>
    <time_frame>within 29 days after the first dose</time_frame>
    <description>Blood samples will be taken to measure the levels of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>within 30 days after the last dose</time_frame>
    <description>the proportion of subjects who have a Complete Response or Partial Response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events evaluated by NCI CTCAE v4.03</measure>
    <time_frame>from the first dose to within 30days after the last dose</time_frame>
    <description>Incidence of adverse events and associated dose of HMPL-523</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>HMPL-523</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration, at a dose of 100, 200, 400, 600, 800 and 1000mg once daily or 300mg and 400mg twice daily at Dose-escalation stage.&#xD;
At the Dose-expansion stage, HMPL-523 600mg will be dosed once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-523</intervention_name>
    <description>Oral administration, once daily</description>
    <arm_group_label>HMPL-523</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form.&#xD;
&#xD;
          2. Ability to comply with the protocol.&#xD;
&#xD;
          3. Age&gt;=18 years.&#xD;
&#xD;
          4. ECOG performance status of 0 or 1.&#xD;
&#xD;
          5. Histologically relapsed or refractory chronic lymphocytic leukemia, lymphoma, multiple&#xD;
             myeloma(MM) In the dose expansion stage, the tumor types are restricted to relapsed or&#xD;
             refractory CLL/SLL, MCL, FL (Grade 1-3a), MZL and WM/LPL.&#xD;
&#xD;
          6. Have failed at least one prior therapy or patients who are unable to tolerate standard&#xD;
             therapy or no curative therapy or therapy of higher priority exists.&#xD;
&#xD;
          7. In the dose-expansion stage, patients must have measurable disease for objective&#xD;
             response assessment.&#xD;
&#xD;
             NOTE: measurable disease with FL, MCL, MZL, LPL, or SLL defined as at least 1&#xD;
             bi-dimensionally measurable lesion (&gt;1.5 cm in its largest dimension by computerized&#xD;
             tomography [CT] scan)., as defined in appendix 9.&#xD;
&#xD;
          8. Expected survival of more than 24 weeks as determined by the investigator.&#xD;
&#xD;
          9. Male or female patients of child-bearing potential must agree to use double barrier&#xD;
             contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device&#xD;
             (IUD), contraceptives (oral or parenteral), Implanon®, injectables or other avoidance&#xD;
             of pregnancy measures during the study and for 90 days after the last day of&#xD;
             treatment. Post-menopausal females (&gt;45 years old and without menses for &gt;1 year) and&#xD;
             surgically sterilized females are exempt from this criterion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with primary CNS lymphoma.&#xD;
&#xD;
          2. Known active central nervous system or leptomeningeal lymphoma.&#xD;
&#xD;
          3. Any of the following laboratory abnormalities:&#xD;
&#xD;
               1. Absolute neutrophil count&lt;1.5×109/L&#xD;
&#xD;
               2. Hemoglobin &lt;80g/L.&#xD;
&#xD;
               3. Platelet&lt;75 ×109/L. NOTE: in expansion stage patients with cell counts below the&#xD;
                  thresholds listed above may be considered eligible if in the investigators&#xD;
                  opinion the reason is believed to be due to bone marrow infiltration. The&#xD;
                  investigator will discuss the eligibility of such patients with the sponsor and&#xD;
                  only upon approval (confirmed in writing) by the sponsor will a patient be&#xD;
                  enrolled in the study.&#xD;
&#xD;
          4. Inadequate organ function, defined by the following:&#xD;
&#xD;
               1. Total bilirubin &gt;1.5the ULN with the following exception:&#xD;
&#xD;
                  Patients with known Gilbert disease who have serum bilirubin level ≤3 the ULN and&#xD;
                  normal AST/ALT may be enrolled.&#xD;
&#xD;
               2. AST and/or ALT &gt; 2.5 the ULN with the following exception:Patients with&#xD;
                  documented disease infiltration of the liver may have AST and/or ALT levels ≤ 5&#xD;
                  the ULN.&#xD;
&#xD;
               3. Serum creatinine &gt; 1.5 the ULN or estimated creatinine clearance &lt; 50 mL/min.&#xD;
&#xD;
               4. Serum amylase or lipase &gt; the ULN.&#xD;
&#xD;
               5. Triglycerides and/or cholesterol &gt;1.5 the ULN.&#xD;
&#xD;
               6. International normalized ratio (INR)&gt;1.5 the ULN or activated partial&#xD;
                  thromboplastin time (aPTT)&gt;1.5 the ULN.&#xD;
&#xD;
             For patients requiring anticoagulation therapy with warfarin, a stable INR between 2-3&#xD;
             is required. If anticoagulation is required for a prosthetic heart valve, then INR&#xD;
             should be between 2.5-3.5 for eligibility NOTE: patients may be considered for the&#xD;
             study if liver or kidney function is impaired, but this impairment is believed to be a&#xD;
             result of the patient's underlying disease. The investigator will discuss the&#xD;
             eligibility of such patients with the Sponsor and only upon approval (confirmed in&#xD;
             writing) by the Sponsor will a patient be enrolled in the study.&#xD;
&#xD;
          5. Subjects with presence of clinically detectable second primary malignant tumors at&#xD;
             enrollment, or other malignant tumors within the last 2 years (with the exception of&#xD;
             radically treated basal cell or squamous cell carcinoma of the skin, in situ cervix,&#xD;
             or in situ breast cancer).&#xD;
&#xD;
          6. Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy,&#xD;
             or radiotherapy within 3 weeks prior to initiation of study treatment.&#xD;
&#xD;
          7. Herbal therapy ≤1 week prior to initiation of study treatment.&#xD;
&#xD;
          8. Prior use of any anti-cancer vaccine.&#xD;
&#xD;
          9. Prior treatment with any SYK inhibitors (e.g. Fostamatinib).&#xD;
&#xD;
         10. Prior administration of radioimmunotherapy 3 months prior to initiation of study&#xD;
             treatment.&#xD;
&#xD;
         11. Taking strong CYP3A inhibitors, and inducers and drugs metabolized by CYP3A, 2B6 and&#xD;
             1A2 that are identified as narrow therapeutic drugs within 7 days or 3 half-lives,&#xD;
             whichever is longer, prior to administration of the first dose of study drug (refer to&#xD;
             Appendix 15).&#xD;
&#xD;
         12. Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤1,&#xD;
             except for alopecia.&#xD;
&#xD;
         13. Prior autologous transplant within 6 months prior to first dose of study drug.&#xD;
&#xD;
         14. Prior allogeneic stem cell transplant within 6 months prior to initiation of study&#xD;
             treatment or with any evidence of active graft versus host disease or requirement for&#xD;
             immunosuppressants within 28 days prior to initiation of study treatment.&#xD;
&#xD;
         15. Clinically significant active infection (pneumonia)&#xD;
&#xD;
         16. Major surgical procedure within 4 weeks prior to initiation of study treatment.&#xD;
&#xD;
         17. Clinically significant history of liver disease, including cirrhosis, current alcohol&#xD;
             abuse, or current known active infection with HIV, hepatitis B virus (HBV), or&#xD;
             hepatitis C virus (HCV).&#xD;
&#xD;
             Active infection is defined as requiring treatment with antiviral therapy or presence&#xD;
             of positive test results for hepatitis B (hepatitis B surface antigen and/or total&#xD;
             hepatitis B core antibody) or HCV antibody.&#xD;
&#xD;
             Patients who test positive for hepatitis B core antibody are eligible only if test&#xD;
             results are also positive for hepatitis B surface antibody and polymerase chain&#xD;
             reaction (PCR) is negative for HBV DNA.&#xD;
&#xD;
             Patients who are positive for HCV serology are only eligible if testing for HCV RNA is&#xD;
             negative.&#xD;
&#xD;
         18. Pregnant (positive pregnancy test) or lactating women.&#xD;
&#xD;
         19. New York Heart Association (NYHA) Class II or greater congestive heart failure.&#xD;
&#xD;
         20. Congenital long QT syndrome or QTc &gt; 450 msec.&#xD;
&#xD;
         21. Currently use medication known to cause QT prolongation or Torsades de Pointes&#xD;
             (http:// www.crediblemeds.org)&#xD;
&#xD;
         22. History of myocardial infarction or unstable angina within 6 months prior to&#xD;
             initiation of study treatment.&#xD;
&#xD;
         23. History of stroke or transient ischemic attack within 6 months prior to initiation of&#xD;
             study treatment.&#xD;
&#xD;
         24. Inability to take oral medication, prior surgical procedures affecting absorption, or&#xD;
             active peptic ulcer disease.&#xD;
&#xD;
         25. Image evidence of gallstone or other bile duct disease within 6 months prior to&#xD;
             initiation of study treatment.&#xD;
&#xD;
         26. Treatment within a clinical study within 30 days prior to initiation of study&#xD;
             treatment.&#xD;
&#xD;
         27. Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of&#xD;
             a disease or condition that contraindicates the use of an investigational drug or that&#xD;
             may affect the interpretation of the results or renders the patient at high risk from&#xD;
             treatment complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen Yu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison Medi Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Canberra</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology Research Unit</name>
      <address>
        <city>Albury</city>
        <state>New South Wales</state>
        <zip>2640</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Townsville</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballarat Regional Integrated Cancer Centre</name>
      <address>
        <city>Ballarat</city>
        <state>Victoria</state>
        <zip>3350</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula &amp; South Eastern Haematology and Oncology Group</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barwon Health</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>September 10, 2020</last_update_submitted>
  <last_update_submitted_qc>September 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

